Valoctocogene roxaparvovec
Valoctocogene roxaparvovec is a biological therapy with 7 clinical trials. Currently 2 active trials ongoing. Historical success rate of 80.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
0
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
80.0%
4 of 5 finished
20.0%
1 ended early
2
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A
Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5
Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors
Gene Therapy Study in Severe Haemophilia A Patients (270-201)
Clinical Trials (7)
Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A
Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5
Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors
Gene Therapy Study in Severe Haemophilia A Patients (270-201)
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg
All 7 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 7